Researchers have found preliminary evidence that combining the psychedelic compound psilocybin with cognitive behavioral therapy can safely and effectively reduce major depressive disorder. With a targeted treatment program, most participants experienced a significant reduction in their symptoms of depression, with more than half in complete remission. This early stage clinical research Affective Disorders Journal.
Psilocybin is an active psychedelic compound naturally produced by dozens of species of fungi. Clinical trials over the past decade have shown that this compound has powerful antidepressant effects when administered alongside psychological support. Several previous studies have shown that this combined approach provides greater symptom relief than standard psychiatric medications or stand-alone talk therapy alone.
The psychological support provided in early trials was mostly non-directive and vaguely defined. In many successful clinical trials of psychedelic medicine, scientists have not published specific treatment manuals. They often refuse to reveal what the treatment part actually means. It often remains unclear what precise conversational techniques a treating psychotherapist utilizes to guide a patient through the experience.
Clinical psychologist Mark J. Weintraub and a team of mental health experts at the University of California, Los Angeles, reasoned that a more structured approach could optimize this new psychiatric tool. They hypothesized that a combination of pharmacotherapy and cognitive-behavioral therapy might yield better long-term results than unstructured conversations. This common form of talk therapy focuses on helping patients identify and modify negative thought patterns and maladaptive behaviors.
Psychotherapies that rely on cognitive-behavioral techniques are widely used and extensively tested as treatments for clinical depression. Mental health practitioners use these strategies to help patients understand and adjust their core beliefs about themselves and the wider world. This treatment approach benefits from a standardized operating manual and has high clinical utility for researchers wishing to replicate successful treatments in a variety of clinical settings.
To test the basic feasibility and safety of this combined approach, Weintraub and the research team recruited 16 adults in the Los Angeles area. Each volunteer was actively experiencing moderate to severe depressive symptoms. Regarding safety parameters, researchers excluded participants with active suicidal ideation, underlying psychotic disorder, or recent history of recreational use of psychedelic drugs.
Prior to participating in the treatment trial, all participants completed a thorough physical and psychological screening process at the university. This screening stage required a general physical exam, an electrocardiogram to check for basic heart health, and standard blood tests. A research psychologist then conducted a diagnostic interview to ascertain the exact nature of the volunteers’ mental health problems.
The actual treatment program spanned 4 months and included a total of 12 1-hour psychotherapy sessions. The treatment component occurred very frequently at the beginning of the study, with the first 9 sessions occurring weekly. Eventually, toward the end of the treatment period, the schedule tapered to three sessions every other week.
After the third and sixth treatment appointments, participants received psilocybin in a controlled clinical setting. To safely introduce the psychedelic drug, the researchers administered doses as low as 10 milligrams during the first dosing session. The patient’s dose was then increased to 25 milligrams with a second dose a month later.
On medication days, participants were required to stay in a dedicated medical room for 6 to 8 hours. Patients rested on a comfortable sofa, wore soft eyeshades, and listened to a carefully selected playlist of ambient and classical music through headphones. Two clinicians remained in the room throughout the hallucinatory experience.
The attending clinician checked the participants’ vital signs every hour. They also provided physical and emotional support if the subjects felt anxious when the drug’s effects peaked. Doctors were on hand throughout the surgery to deal with any unexpected medical emergencies.
After the first dosing day, subsequent weekly psychotherapy sessions focused on integrating the lessons learned from the psychedelic experience. The therapist worked with the patient to practice behavioral activation, which involves intentionally scheduling pleasurable daily activities to naturally boost mood. The final talk therapy session focused on establishing a workable plan to prevent future relapses by identifying early warning signs of depressive episodes.
Numerical results from the pilot study highlighted high acceptability and clinical retention among trial volunteers. All 16 adults actively participated in the program until the final follow-up assessment 3 months after the end of formal treatment. One participant discontinued a second dose of medication due to an unrelated medical issue but chose to complete the entire talk therapy series.
Survey feedback from both patients and clinicians suggested that they felt the structure and duration of the combination therapy was very appropriate. Several participants recommended that future iterations of the program introduce cognitive skills training earlier in the timeline. Some volunteers also noted that their assigned treatment goals sometimes changed because they suddenly had personal insights while the subjective effects of the psychedelic drug were at their peak.
Any physical adverse reactions directly resulting from the medication were quite mild and resolved on their own within a few days. The most commonly reported physical side effects included headache, nausea, and mild gastrointestinal discomfort. The researchers reported that there were zero serious medical incidents at any point during the clinical trial.
Independent raters who measured long-term mood and functional outcomes observed significant improvements in overall mental health. By the end of the 4-month treatment period, 13 participants showed moderate to large reductions in standardized depression scores. Nine participants achieved complete remission, meaning that their daily depressive symptoms essentially disappeared.
These immense mental health benefits remained highly stable throughout the 3-month follow-up evaluation period. The researchers used a separate rating scale to track momentary mood states and found that participants experienced immediate relief from their depressive mood immediately after administering the psychedelic drug. Their mood scores eventually stabilized at levels significantly lower than their original baseline measurements.
The researchers also investigated what cognitive mechanisms facilitate this profound symptom relief. They observed that lower global depression scores coincided with improved emotion regulation abilities. Participants expressed a newfound ability to overcome overwhelming or chaotic inner feelings.
Additionally, volunteers reported developing more positive schemas, which are the basic frameworks and beliefs that people have about themselves and the people around them. The researchers noted that the improvement in positive self-referential thoughts completely outweighed the decrease in negative thoughts. They recommend that future treatments may benefit from focusing on enhancing the positive emotions derived from psychedelic experiences, rather than trying to eliminate negative emotions completely.
Because this was an exploratory pilot study, the researchers acknowledge that there are some limitations to the initial experimental design. There was no placebo group in this study. This meant that all enrolled participants knew they were receiving active medication. This open-label format does not allow us to definitively rule out a placebo effect. Based on these preliminary numbers, it is inherently difficult to determine the exact extent to which medication and intensive talk therapy have reduced symptoms.
The independent raters who evaluated the participants may have inadvertently developed unconscious expectations because they knew that the participants were actively engaged in treatment. The study was also limited to physically healthy individuals who were not currently taking standard serotonergic antidepressants. This demographic constraint limits the immediate applicability of our findings to the broader public.
Future clinical research should include larger randomized controlled trials that directly compare this precise treatment approach with other forms of psychological support. Such extensive research will help scientists determine whether certain treatment styles work better with psilocybin than others. Finding the perfect fit could ultimately allow clinicians to better customize psychotherapy for the millions of people diagnosed with major depressive disorder.
The study, “Psilocybin-Assisted Cognitive Behavioral Therapy for Major Depressive Disorder: A Pilot Trial,” was authored by Mark J. Weintraub, Jessica K. Jeffrey, Megan C. Ichinose, R. Lindsey Bergman, Benjamin Shapiro, Gregory Barnett, Hewa Altin, Mark Lin, Annabelle Salimian, Shelby Grody, Rahul Ramesh, and Lauren. Eales, Charles S. Grob, and David J. Mikowitz.
